Dan McCoy MD Named Chief Medical Officer at Catapult Health

Catapult’s forward-looking innovation and leadership in virtual clinical care were key drivers in bringing McCoy and Michel together

Dan McCoy MD will provide clinical and strategic leadership to the company as he joins Catapult’s executive team.

Dr. McCoy is a physician, entrepreneur, and communicator who is passionate about improving the way healthcare is delivered. In his time as president of Blue Cross and Blue Shield of Texas, he was instrumental in the creation of the C1 Innovation Lab in Dallas, with the goal of uniting clinicians, members, advocates, and innovators to work together to generate solutions. Dr. McCoy’s previous roles at BCBSTX included divisional senior vice president of the Texas market strategy, and Texas plan chief medical officer. During his term as president (2016-2020), BCBSTX experienced the largest growth in membership, underwriting margin and revenue in the company’s 90-year history.

“I’m excited about the opportunity to contribute to the already great work of Catapult Health,” said Dr. McCoy. “I’ve watched them from their early days and have always been impressed with how well they’ve focused on the patient, while being nimble and responsive to major changes in the healthcare environment.”

“I’ve known and worked with Dr. McCoy for the better part of a decade, and now is the perfect time for him to join our team,” said Michel. “Over the past year, we created and launched the nation’s first VirtualCheckup®, leveraging our world-class clinical expertise, sophisticated technology, and ability to scale up quickly. Dr. McCoy’s skills and experiences are very well matched with our go-forward strategy.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version